Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg

Abstract Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study. Here, we report data from children aged ≥2 years and weighing ≥14–<25 kg. Method...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Natukunda, Aditya H. Gaur, Pope Kosalaraksa, Elizabeth Hellström, Renate Strehlau, Afaaf Liberty, Stephanie Cox, Rory Leisegang, Ramesh Palaparthy, Susanne Crowe, Vinicius Vieira, Kathryn Kersey, Natella Rakhmanina
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Journal of the International AIDS Society
Subjects:
antiretroviral therapy
children
E/C/F/TAF
elvitegravir
HIV‐1
tenofovir alafenamide
Online Access:https://doi.org/10.1002/jia2.26414
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jia2.26414

Similar Items